The expanding field of metabolic peptide research continues to explore next-generation compounds that modulate appetite, glucose homeostasis, and energy expenditure. Among these, Mazdutide (also known as IBI362) has gained attention for its dual agonist activity at both the GLP-1 and glucagon receptors (Jiang et al.; Gutgesell et al.). While newer than widely discussed peptides like Tirzepatide and Retatrutide, Mazdutide offers a distinct receptor profile and therapeutic rationale that make it highly relevant to ongoing studies in obesity and metabolic disorders (Winther & Holst; Huang et al.).
This blog outlines the key properties of Mazdutide, its mechanisms of action and research benefits, and provides comparisons with other incretin-pathway peptides under investigation for metabolic disorders.
Mazdutide is a synthetic investigational peptide designed as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR). It belongs to a class of incretin-based peptides that aim to replicate or enhance the effects of endogenous hormones involved in satiety, glucose metabolism, and lipid mobilization (Jiang, Gutgesell et al.).
Unlike simple GLP-1 receptor agonists, Mazdutide activates both GLP-1 and GCGR pathways. This dual activity allows it to engage broader metabolic systems—enhancing insulin secretion, suppressing appetite, and promoting energy expenditure through increased thermogenesis and lipid oxidation (Winther & Holst, Christoffersen et al., Newsome & Ambery).
Mazdutide binds to and activates GLP-1 receptors, stimulating insulin secretion, slowing gastric emptying, and suppressing appetite (Dong). Simultaneously, it engages the glucagon receptor, promoting lipolysis and increasing basal metabolic rate through hepatic and adipose tissue pathways (Jiang). The combined activity is hypothesized to produce synergistic effects on weight loss and glycemic regulation (Winther).
Its dual-receptor profile distinguishes it from single-pathway agents like Semaglutide, offering a broader metabolic influence by incorporating both nutrient-sensing and energy-expending mechanisms (Huang).
As a dual agonist targeting both the GLP-1 receptor and the glucagon receptor (GCGR), Mazdutide has attracted increasing interest in metabolic research due to its unique physiological profile. Unlike single-target peptides, Mazdutide’s dual mechanism offers the potential to address multiple metabolic pathways simultaneously, opening avenues for more comprehensive experimental models (Ji et al.).
Key research benefits include:
By activating GCGR, Mazdutide may stimulate energy expenditure in addition to the appetite-suppressing effects mediated by GLP-1R. This dual action is being explored in research on obesity and metabolic syndrome (Winther & Holst).
Like other GLP-1 agonists, Mazdutide supports glucose homeostasis by enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner. These properties make it relevant for type 2 diabetes models (Deng et al.).
Preclinical studies suggest that Mazdutide may enhance fat utilization and reduce lipogenesis, providing a unique research profile for studies focused on lipid regulation (Jiménez-Martí & Hurtado-Genovés).
Initial models have examined Mazdutide’s effects on blood pressure, heart rate, and inflammatory markers, indicating its potential value in broader cardiometabolic disease research (Dong et al.).
Importantly, Mazdutide’s balance between GLP-1 and glucagon receptor activation appears to influence the magnitude and tolerability of metabolic responses, offering researchers a controlled platform to study the physiological interplay between satiety, energy balance, and glucose control.
Tirzepatide is a dual GLP-1/GIP receptor agonist known for its strong glucose-lowering and weight-reduction effects (Zhou et al.; Liu et al.). Unlike Mazdutide, Tirzepatide does not activate the glucagon receptor but instead targets GIP (glucose-dependent insulinotropic polypeptide) to enhance insulin secretion and beta-cell function (Liu et al.).
To learn more about Tirzepatide’s structure and uses, read:
Although both Mazdutide and Tirzepatide are incretin-based peptides studied in metabolic research, they differ in receptor targeting and physiological outcomes. Mazdutide functions as a dual GLP-1 and glucagon receptor agonist, supporting glucose regulation while also promoting energy expenditure through glucagon signaling (Huang et al.; Folli et al.). Tirzepatide, by contrast, activates GLP-1 and GIP receptors, emphasizing appetite suppression and improved insulin sensitivity (Jiang et al.). While Tirzepatide is often used in models focused on glycemic control and satiety, Mazdutide provides a more targeted approach for exploring glucagon-mediated effects on lipid metabolism and thermogenesis (Winther & Holst).
Retatrutide is a triple agonist targeting GLP-1, GIP, and GCGR receptors, making it a broader agent than Mazdutide in terms of receptor engagement. Retatrutide’s triple-receptor activity is designed to offer comprehensive metabolic modulation, combining incretin hormone effects with energy expenditure stimulation (Li et al.; Kaur & Misra).
For a full overview of Retatrutide’s structure and emerging research potential, stay tuned for our upcoming blog:
Mazdutide and Retatrutide share similarities in targeting the GLP-1 and glucagon receptors, but Retatrutide also includes GIP receptor activation, making it a triple agonist. This added receptor activity allows Retatrutide to influence a wider array of metabolic pathways, making it especially relevant in studies of obesity, insulin resistance, and multi-hormonal regulation. Mazdutide, on the other hand, offers a more streamlined dual-agonist model that is particularly useful for investigating the balance between satiety, glucose control, and fat oxidation. Researchers may choose between them depending on whether a focused or broader incretin pathway study is desired (McGlone & Tan; Folli et al.).
Several other research peptides are often used in the study of metabolism and weight regulation:
These peptides vary in receptor targets and biological outcomes, but together form a valuable reference set for comparative metabolic peptide research.
|
Peptide |
Receptor Targets |
Mechanism |
Primary Research Focus |
|
GLP-1, GCGR |
Appetite suppression, lipid oxidation |
Weight loss, thermogenesis, glycemic support (Jiang) |
|
|
GLP-1, GIP |
Incretin enhancement, insulin secretion |
Weight loss, beta-cell function, diabetes (Idris) |
|
|
GLP-1, GIP, GCGR |
Full incretin + energy expenditure pathway |
Obesity, glucose regulation, energy homeostasis (Akhond; Misra) |
|
|
GLP-1 |
Appetite control, insulin sensitivity |
Type 2 diabetes, weight reduction (Mu) |
|
|
GHRH receptor (indirect) |
GH/IGF-1 axis stimulation ; |
Muscle growth, recovery, fat metabolism (Teichman et al.) |
|
|
GH fragment (non-GH receptor) |
Direct lipolytic activity |
Fat loss, obesity models (Moré & Kenley) |
While Mazdutide itself is still under active investigation and not yet widely available, Polaris Peptides provides a trusted source for research-grade peptides involved in metabolic and endocrine research. Our selection includes compounds like Tirzepatide, CJC-1295, and AOD-9604, all of which are rigorously tested for purity and consistency.
Researchers looking to expand their studies into the mechanisms of peptide-based weight regulation can rely on Polaris for access to reliable and high-quality peptide materials.
As interest in multi-agonist peptides grows, Mazdutide represents a focused and potent tool for investigating the intersection of appetite regulation, energy expenditure, and metabolic balance. Its dual action on GLP-1 and glucagon receptors places it between the incretin-based approach of Tirzepatide and the more comprehensive triple-agonist profile of Retatrutide.
For researchers designing peptide-based interventions or modeling complex metabolic conditions, understanding how these peptides differ—mechanistically and functionally—is critical. Whether the focus is on incretin signaling, lipid metabolism, or thermogenic regulation, Mazdutide offers a unique angle within the broader spectrum of metabolic research.
High-quality compounds like Mazdutide are essential for advancing experimental reliability. Polaris Peptides provides rigorously tested peptides for laboratory use, supporting scientific discovery across the growing field of metabolic peptide research.
Discount Applied Successfully!
Your savings have been added to the cart.
Join our Polaris Insiders program to get rewarded for loyalty with exclusive deals, news about upcoming products, and more.
You must be 21 years old or older in order to access our website. Please verify your age.
Our products are crafted for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease.